Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07213973 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 14 words Secondary endpoints: details revised at 1 of 11 entries · Site details revised at 1 of 30 sites Show 2 more changesShow less
    • Secondary endpoints: details revised at 1 of 11 entries
    • Site details revised at 1 of 30 sites
  2. Site details revised at 1 of 30 sitesv16
  3. Site details revised at 1 of 30 sitesv15
  4. Site details revised at 1 of 30 sitesv14
  5. Site details revised at 1 of 30 sitesv13
Show 11 earlier versionsHide 11 earlier versions
  1. Study sites: 29 to 30v12
  2. Study sites: 27 to 29v11
  3. Site details revised at 2 of 27 sitesv10
  4. Site details revised at 2 of 27 sitesv9
  5. Study sites: 29 to 27v8
  6. Site details revised at 1 of 29 sitesv7
  7. Study sites: 30 to 29v6
  8. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 14, 2025 to Feb 2, 2026 · Study sites revised (30)v5 Show 2 more changesShow less
    • Start date changed from estimate of Dec 14, 2025 to Feb 2, 2026
    • Study sites revised (30)

    See this version in full on ClinicalTrials.gov ↗

  9. Study sites: 29 to 30v4
  10. Study sites: 0 to 29 Secondary endpoints revised (11)v3 Show 1 more changeShow less
    • Secondary endpoints revised (11)

    See this version in full on ClinicalTrials.gov ↗

  11. Study Status, Referencesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
Trial Details
NCT Number NCT07213973
Lead Sponsor Incyte Corporation
Conditions Hidradenitis Suppurativa (HS)
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov